Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States

25Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Early death (ED) occurs in 10-30% of patients with acute promyelocytic leukemia (APL). Is all- trans retinoic acid (ATRA) promptly given and does it decrease overall early mortality? ATRA was administered within 24. h of morphological suspicion in only 44% of the 120 consecutive patients treated in the four collaborating centers. Absence of disseminated intravascular coagulation (p= 0.012) and admission to a non-university-affiliated hospital (p= 0.032) were independent predictors of ATRA delay. ED occurred in 17% of patients, and was independently correlated only with ICU admission (p= 0.002). Our results do not demonstrate that prompt (versus delayed) ATRA administration decreases overall early death. © 2014 Elsevier Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Rashidi, A., Riley, M., Goldin, T. A., Sayedian, F., Bayerl, M. G., Aguilera, N. S., … Fisher, S. I. (2014). Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States. Leukemia Research, 38(9), 1036–1040. https://doi.org/10.1016/j.leukres.2014.06.011

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free